Lexiscan Disease Interactions

The use of regadenoson has been associated with fatal and nonfatal myocardial infarction, ventricular arrhythmias, and cardiac arrest. Therapy with regadenoson should be avoided in patients with symptoms or signs of acute myocardial ischemia, such as unstable angina or cardiovascular instability as these patients may be at greater risk of serious cardiovascular reactions. Appropriate monitoring and equipment for resuscitation should be available before administering regadenoson. If serious reactions to regadenoson occur, consider the use of aminophylline, an adenosine antagonist, to shorten the duration of increased coronary blood flow induced by regadenoson administration.

The use of regadenoson is contraindicated in patients with second- or third- degree AV block, or with sinus node dysfunction in the absence of a functional artificial pacemaker. Adenosine receptor agonists, including regadenoson, can depress the SA and AV nodes and may cause first-, second- or third-degree AV block, or sinus bradycardia requiring intervention.

New-onset or recurrent atrial fibrillation with rapid ventricular response and atrial flutter, and cardiac arrest have occurred following regadenoson injection. Therapy with regadenoson should be administered cautiously in patients with cardiac conduction disorders.

The use of regadenoson, as others adenosine receptor agonist may induce dyspnea, bronchoconstriction and respiratory compromise in patients with COPD or asthma. Appropriate bronchodilator therapy and resuscitative measures should be available prior to regadenoson administration.

The use of adenosine receptor agonists, including regadenoson, has been associated with arterial vasodilation and hypotension. The risk of serious hypotension may be higher in patients with autonomic dysfunction, hypovolemia, left main coronary artery stenosis, stenotic valvular heart disease, pericarditis or pericardial effusions, or stenotic carotid artery disease with cerebrovascular insufficiency.

The use of regadenoson may lower the seizure threshold. New-onset or recurrence of convulsive seizures has occurred following regadenoson injection. Caution is recommended when using this agent in patients with or predisposition to seizure disorders.